THERAPEUTICS SYMPOSIUM 2024

# BRINGING DISCOVERIES TO LIFE

TUESDAY, 2ND JULY
WEST ROAD CONCERT HALL, CAMBRIDGE & ONLINE

UNIVERSITY OF CAMBRIDGE

MILNER THERAPEUTICS INSTITUTE


MILNER
THERAPEUTICS INSTITUTE
ringing Discoveries
to Life


MILNER
PHOREMOST
ABOUT US
OUR TECHNOLOGY
OUR STRATEGY

# PROGRAMME 2 JULY 2024

| | |
|---|---|
| 10:30 – 12:00 | Meet the Consortium session<br>(*meetings by advance request only*) |
| *12:00 – 1:00* | *Buffet lunch* |
| SESSION ONE | **Chaired by Bradley Hardiman, Astellas Pharma Inc.** |
| 1:00 – 1:15 | **Tony Kouzarides and Cathy Tralau-Stewart**, Milner Therapeutics Institute<br>*Welcome and Introduction* |
| 1:15 – 1:45 | **Todd Golub**, Broad Institute<br>*"Perspectives on genomic approaches to cancer precision medicine"* |
| 1:45 – 2:15 | **Steve Jackson**, CRUK Cambridge Institute, University of Cambridge<br>*"Translating blue-skies research towards new medicines: a personal perspective"* |
| 2:15 – 2:45 | **Simone Fishburn,** BioCentury<br>*"Upstream of early: where biotech meets academia to drive the next era of medicines"* |
| *2:45 – 3:30* | *Break and Poster Session* |
| SESSION TWO | **Chaired by Julia Wilson, Wellcome Sanger Institute** |
| 3:30 – 4:00 | **Dave Hallett,** Exscientia<br>*"Human-led AI drug discovery"* |
| 4:00 – 4:30 | **Sarah Teichmann**, Cambridge Stem Cell Institute, University of Cambridge<br>*"Translating the human cell atlas"* |
| 4:30 – 5:00 | **Jill Richardson**, MSD<br>*"Advances in CNS drug discovery: the application of new approaches in neurodegenerative diseases"* |
| *5.00 – 6:30* | *Networking and Poster Session* |

SESSION I

SESSION 1

CHAIR
**BRADLEY HARDIMAN**
*Astellas Pharma Inc.*

## BRADLEY HARDIMAN

*Astellas Pharma Inc.*

**BIOGRAPHY** | Bradley started his career in large pharma, conducting basic research in drug discovery. He has since amassed over 20 years' experience in technology transfer, business development and venture capital investment.

He spent seven and a half years within the Seed Funds team at Cambridge Enterprise, the commercialisation arm of the University of Cambridge. There he assessed, helped create, and invested in, a number of spin-outs founded on University research. These spin-outs spanned numerous areas including therapeutics (including small molecules, biologics and gene therapy), diagnostics, prognostics, medical devices, scientific instrumentation, reagents and digital health.

He has an appreciation of design, having spent time running the incubator at Design London, a partnership between the Royal College of Art (RCA) and Imperial College London. He is currently a Visiting Business Fellow at InnovationRCA, the commercialisation arm of the RCA. There he coaches design led start-ups coming from this world class institution. He also sits on the Investment Advisory Panel of their venture fund.

He is currently within the Business Development team at Astellas Pharmaceuticals. His main duty in this role is as part of Astellas' corporate venture arm, AVM, investing in early-stage companies of interest to Astellas Pharma Inc. He also scouts for collaboration, licensing and M&A opportunities which are also within Astellas' areas of interest.

He holds an Undergraduate Degree in Medical Biochemistry from Brunel University, a Research Master's Degree in Molecular Biochemistry from the University of Cambridge, and an Executive MBA from Bayes (formerly Cass) Business School.

## TONY KOUZARIDES

*Director,*
*Milner Therapeutics Institute*

**BIOGRAPHY** | Sir Tony Kouzarides is Professor of Cancer Biology at the University of Cambridge and a Senior Group Leader at the Gurdon Institute. Tony is also the director and co-founder of the Milner Therapeutics Institute at the University of Cambridge, which has a mission to deliver better therapies by connecting academia with business.

The Kouzarides Lab has been studying epigenetic modifications of histones and RNA, has over 200 publications, and close to 96,000 citations. A cancer gene identified in his lab (the METTL3 RNA methyltransferase) has been targeted for drug discovery in a collaboration with STORM Therapeutics. This drug is currently in clinical trials against cancer.

Tony is founder/director of Cambridge Gravity, an organization that promotes entrepreneurship at the University of Cambridge. He is founder and ex-director of a cancer charity in Spain called Conquer Cancer (Vencer el Cancer), and a co-founder of four companies, Abcam plc, Chroma Therapeutics, STORM Therapeutics and VELLOS.

In 2024, Tony was awarded the honour of a knighthood for services to healthcare innovation and delivery. Tony has been elected Fellow of the Royal Society (FRS), Fellow of the British Academy of Medical Sciences (FMedSci), Fellow of the American Academy of Arts and Sciences (AAAS), Fellow of the Cyprus Academy of Science, and is a Cancer Research UK Gibb Fellow. He has been awarded the Wellcome Trust Award for Research in Biochemistry Related to Medicine (UK), the Tenovus Medal (UK), the Bodossaki Foundation prize in Biology (Greece), the Bijvoet Medal (Holland), the Biochemical Society Award, Novartis Medal and Prize (UK), the Heinrich Wieland Prize (Germany) and the Excellence in Science Award (Cyprus).

## CATHY TRALAU-STEWART

*Executive Director,*
*Milner Therapeutics Institute*

**BIOGRAPHY** | Cathy Tralau-Stewart is Executive Director of The Milner Therapeutics Institute. Cathy is a pharmacologist who has worked in early drug discovery for over thirty years. Her experience ranges from target discovery through to early clinical assessment in a wide range of therapeutic areas, and her track record includes material involvement in many marketed products and candidate compounds. Cathy has been involved in the advising, evaluation and due diligence of >500 projects, and has supported and enabled the translation of many therapeutic technologies from academia towards the clinic.

Following her PhD in Clinical Sciences at University College London (UCL), Cathy worked in GI, oncology and then respiratory clinical & pre-clinical R&D at GSK. She founded and directed the Drug Discovery Centre, Imperial College London (2007-2012), and directed the University of California San Francisco (UCSF) Catalyst Translational Program (2013), where she was also an advisor for Stanford University SPARK. She was an Adjunct Associate Professor, Bioengineering and Therapeutic Sciences at UCSF, a Visiting Scholar at Stanford, and a founder of the cross campuses University of California Drug Discovery Centre.

Cathy has held senior leadership positions at Takeda Pharmaceuticals in External Innovation, leading an extensive network of academic alliances along the West Coast (UC San Diego, Stanford University, The University of Washington and The Fred Hutch Cancer Centre, Seattle). Since returning to the UK in 2021, Cathy has held CSO roles at C4X Discovery and currently at ValiRx plc.

Cathy is a member of the Scientific Advisory Board of ELRIG.

## TODD GOLUB

*Broad Institute*

**TALK TITLE** | Perspectives on genomic approaches to cancer precision medicine

**ABSTRACT** | New tools have made it possible to systematically discover new therapeutic approaches to cancer, including the discovery of new targets and the optimal use of existing targeted therapies. In this talk, I will present work from my lab and our collaborators, involving learning from patients using direct-to-patient engagement and learning from experimental models of cancer at scale, using both pooled genome-wide CRISPR screens and multiplexed small-molecule screens using the PRISM method. I will describe recent discoveries that identify emerging mechanisms of cancer drug resistance, the discovery of phosphate homeostasis as a new therapeutic angle in ovarian cancer, and the characterization of mechanisms of action of hypomethylating agents in cancer.

**BIOGRAPHY** | Todd Golub is director and a founding core member of the Broad Institute of MIT and Harvard. Golub is a world leader in using genomics tools to understand the basis of cancer. He also pioneered the development of new cell-based approaches to drug discovery for cancer and other diseases. Golub is the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute, and professor of paediatrics at Harvard Medical School. He is the recipient of multiple awards, including the Outstanding Achievement Award from the American Association for Cancer Research, the Paul Marks Prize for Cancer Research, and the Daland Prize from the American Philosophical Society. In 2014 he was elected to the National Academy of Medicine.

## STEVE JACKSON

*CRUK Cambridge Institute, University of Cambridge*

**TALK TITLE** | Translating blue-skies research towards new medicines: a personal perspective

**ABSTRACT** | Because DNA within cells is frequently subject to various forms of damage, life has evolved various DNA-repair mechanisms and associated processes, collectively termed the DNA-damage response (DDR). The importance of DDR mechanisms is underlined by their deregulation or loss, causing various disorders including cancer, developmental defects, infertility, immune-deficiency, neurodegeneration, and premature ageing. In this talk, I will briefly summarise how my past research in the DDR arena has led me to establish several drug-discovery biotechnology companies. I will then describe how current work in my academic group – combining CRISPR genome engineering and genetic screens with mechanistic studies – is identifying new DDR factors/regulators, defining their functions, and identifying new therapeutic avenues for various serious human diseases.

**BIOGRAPHY** | Sir Steve Jackson is the University of Cambridge Frederick James Quick Professor of Biology, and Senior Group Leader at the CRUK Cambridge Institute (stevejacksonlab.org). His research has discovered how cells respond to and repair DNA damage, and helped define how their dysfunction yields cancer and other diseases. Steve is a fellow of the Royal Society, the UK Academy of Medical Sciences, The European Academy of Cancer Sciences, and EMBO. He has received various national and international prizes, and in 2023 was knighted for his services to innovation and research. Steve has founded several drug-discovery companies, including

KuDOS Pharmaceuticals, which developed and took into first patients the PARP-inhibitor drug Olaparib/Lynparza™, now marketed worldwide for certain ovarian, breast, pancreatic and prostate cancers.

## SIMONE FISHBURN

*BioCentury*

**TALK TITLE** | Upstream of early: where biotech meets academia to drive the next era of medicines

**ABSTRACT** | Investors want to know what is the next innovation that will drive value. Pharma companies want to know what science will shape their pipelines in the next decade. Researchers want a pathway from their discoveries to patients. The interplay between academia and industry, at the very upstream part of the drug development continuum, is foundational to the fabric of biotech. By looking at the numbers and types of technologies coming from academia that are drawing investments and partnerships, and who the players are, BioCentury is mapping the story of where biotech is headed. This talk will look the latest trends of where investors and pharma companies are placing their bets, from the levels of validation to the types of breakthrough that are generating deals.

**BIOGRAPHY** | Simone serves as Editor in Chief at BioCentury, overseeing analysis, research and data across BioCentury's intelligence platform. A bench scientist and translational researcher by background, Simone joined BioCentury in 2013, working initially on innovation and critical issues in translation at the academia/industry interface via BioCentury Innovations. She took leadership of the flagship BioCentury publication in 2018 as Executive Editor, with responsibility for analysis across all stages of drug development, including financing, policy, regulation, and other global issues essential to biotech decision-makers. She was appointed Editor in Chief in 2019. In this role, Simone drives strategic growth of BioCentury's

analysis products, guides coverage of innovation across the ecosystem and oversees content for BioCentury's conferences. She also writes and runs BioCentury's annual Back to School analysis. Simone moderates panels globally on key topics for the biopharma industry and has interviewed thought leaders across the industry, including pharma CEOs, R&D leaders, top VCs and bankers, regulators and more. She is co-host of The BioCentury Show and a regular on the BioCentury This Week podcast. Simone has worked in both industry and academia, running a research lab at Nektar Therapeutics, as a scientific consultant at Exponent Inc., and an independent researcher at the Weizmann Institute of Science. She was an advisor on the SPARK Translational Program at Stanford University from 2011-2022 and the CTSI Catalyst Program at UCSF from 2013-2022. She is an active advocate for advancing women's careers, has written extensively on women in leadership, and was President of Women in Bio from 2013-2014. Simone holds a PhD. from the Weizmann Institute in molecular pharmacology, and an MA and BA in Pharmacology from Cambridge University. Simone is a Fulbright scholar.

SESSION 2

CHAIR
**JULIA WILSON**
*Wellcome Sanger Institute*

SESSION 2

## JULIA WILSON

*Wellcome Sanger Institute*

**BIOGRAPHY** | Julia is the Chief Strategy and Innovation Officer at the Wellcome Sanger Institute. Her primary focus is partnering to advance the reach and impact of the Institute's research within academia, commercial organisations, funders and government(s). Julia oversees organisational Strategy, Funding and Impact, as well as Policy and Advocacy, Translation and Entrepreneurship, and the Academic Programmes. Julia leads relations with key external strategic partners and the Open Targets initiative. Her *Strategy, Partnerships and Innovation* Department delivers insight and impact from the Institute's work to develop strategy, enrich Sanger's scientific work and position the Institute nationally and internationally.

Previously, Julia worked at Breakthrough Breast Cancer and the World Cancer Research Fund. As a scientist, she was a post-doc at the Karolinska Institute Sweden and a researcher at Cancer Research UK and Queen Mary University of London.

Julia is an alumna of the Academy of Medical Sciences FLIER programme, a board member of Cambridge Ahead and Open Targets, and is currently co-leading the Academy of Medical Sciences/National Academy of Medicine initiative on Climate and Health.

## DAVE HALLETT

*Exscientia*

**TALK TITLE** | Human-led AI drug discovery

**ABSTRACT** | The use of advanced generative technologies – commonly called AI – in designing chemical molecules has been well established. However, delivering effective, well-tolerated future drugs will continue to require a blend of the best human science and tech expertise with the capacity of generative technologies. Exscientia's team is focused on leveraging its AI-platforms and emerging technologies to advance and enrich its oncology focused pipeline with new targets. However, the company's experts are also taking the use of innovative technology one decisive step further: by fully integrating human science, AI-led design and comprehensive process automation across the entire drug discovery value chain, Exscientia aims to further cut down the time needed for development of quality drug candidates for clinical development and, ultimately, patients.

**BIOGRAPHY** | Dave Hallett PhD is an experienced 'drug hunter' with a track record of over 20 years leading successful teams and driving major strategic collaborations. He is acting Chief Executive Officer (interim) and Chief Scientific Officer of Exscientia, as well as an Executive Director (interim) of the company's board. He has been Chief Scientific Officer since February 2023 and before that served as Chief Operations Officer from January 2020.

Prior to joining Exscientia, from 2005 to 2019 Dave held various positions within Evotec including Executive Vice President of Chemistry and EVP of Alliance Management. He trained as a medicinal chemist and served as a Research Fellow at Merck & Co.. Dave holds a BA in Natural Sciences from the University of Cambridge, a PhD in Synthetic Organic Chemistry from the University of Manchester and was a post-doctoral fellow in Synthetic Organic Chemistry at the University of Texas, Austin.

## SARAH TEICHMANN

*Cambridge Stem Cell Institute, University of Cambridge*

**TALK TITLE** | Translating the Human Cell Atlas

**ABSTRACT** | The 37 trillion cells of the human body have a remarkable array of specialised functions, and must cooperate and collaborate in time and space to construct a functioning human. Single cell genomics and spatial technologies now help us understand this cellular diversity, how it is generated during development and how it goes wrong in disease. In my talk I will discuss a particularly exciting impact of cell atlasing technologies: the transformation of drug discovery.

**BIOGRAPHY** | Sarah did her PhD at the MRC Laboratory of Molecular Biology (MRC-LMB), Cambridge, and was a Beit Memorial Fellow at University College London. She started her group at the MRC-LMB in 2001, and moved to the Wellcome Genome Campus in 2013, where her group was joint between the EMBL-EBI and the Wellcome Sanger Institute. In 2016 she was appointed Head of the Cellular Genetics programme at the Sanger. Sarah is co-founder and co-leader of the international Human Cell Atlas consortium, which aims to create reference maps for cells across all human tissues, and co-directs the CIFAR MacMillan Multiscale Human research programme. In 2024, Sarah will take up a Chair in Stem Cell Medicine at the University of Cambridge (Cambridge Stem Cell Institute and the Department of Medicine).

## JILL RICHARDSON

*MSD*

**TALK TITLE** | Advances in CNS drug discovery: the application of new approaches in neurodegenerative diseases

**ABSTRACT** | The rapid pace of scientific and technological advances is propelling a new era in biopharmaceutical innovation. Effective collaboration between industry, biotech and academia is critical for the successful translation of basic science through to the clinic. This is particularly evident in complex diseases such as Alzheimer's Disease, Parkinson's Disease and Motor Neuron Disease.

Despite the challenges, MSD has been committed to Neuroscience for many years. In addition to therapeutics aimed at lowering aggregate toxic proteins specific to neurodegenerative diseases, we are also focusing on mechanisms such as oxidative stress, mitochondrial dysfunction, impaired neuroimmune pathways, impaired proteostasis and autophagy. By targeting these pleiotropic mechanisms that may underlie many neurodegenerative diseases we aim to increase our chance of success even in heterogeneous patient populations. Large numbers of novel targets are emerging from genetics and genomic technologies – there is an urgent need to unravel this 'big data' to prioritise the key mechanisms involved with the different neurodegenerative diseases to identify the most tractable targets as well as the central and peripheral biomarkers required to deliver innovative medicines. For such a challenge, there has never been a better time for industry to partner with academia to work on dementia within the U.K. as reflected by the priorities set out by the U.K. Life Sciences Vision but also the multiple investment

projects that have been established to focus on Dementia and Movement disorders.

**BIOGRAPHY** | Dr. Richardson is Executive Director and Head of Biology at the MSD London Discovery Centre, based at the London Bioscience Innovation Centre (LBIC) and is an integral member of the Global Neurosciences Leadership Team. She has an outstanding track record of contribution to neuroscience research and drug discovery within the Pharmaceutical Industry, having spent 23 years at GlaxoSmithKline before joining MSD in 2018. She is leading a portfolio of innovative drug discovery programmes with the aim of developing novel, differentiated medicines for the treatment of diseases of high unmet need, with a focus on neurodegenerative diseases.

After completing a post-doc at the National Institutes of Health, Bethesda, U.S., Dr. Richardson joined GlaxoSmithKline and held several leadership positions including Head of Neurodegeneration Research, Target Validation and Synaptic Plasticity and Neural Network Departments. Her external appointments have included the EFPIA leader of the IMI PharmaCog Alzheimer's Disease, a 38-partner public-private alliance, which delivered a multimodal battery of biomarkers including associating cognitive tests, EEG, MRI and PET-scan, useful for assessment of both symptomatic and drug-disease-modifying drugs across animals, healthy volunteer challenge models and patients. She is a Fellow of the Royal Society of Biology and has a Visiting Professorship at Imperial College London. She has served on several national and international Advisory Boards including the Wellcome Trust, DZNE Senate, MRC DRI Quinquennial panel and ARUK DDI Review Panel. She currently serves as Vice Chair on the My Name'5 Doddie Foundation Research Review Committee and is a member of the Motor Neuron Disease (MND) DRI Industry Panel. With over 135 peer reviewed publications, Dr. Richardson is internationally recognised and has made important contributions to neurological diseases including Alzheimer's disease, Parkinson's disease, MND, multiple sclerosis, pain and epilepsy during her career.

## GLOBAL THERAPEUTIC ALLIANCE

The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration.

Our outreach programme is through the **Global Therapeutic Alliance,** which aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The **Milner Therapeutics Consortium** (*p12*) is central to this aim, and the Alliance has been expanded with the Affiliated Company, Institution, and Venture Partner schemes (pages 20–21, 62 and 63, respectively), to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge.

Research in the Milner Therapeutics Institute is funded by:

CONSORTIUM

## MILNER THERAPEUTICS CONSORTIUM

The Milner Therapeutics Consortium is an academic-industry partnership, active since June 2015. This is underpinned by a Consortium agreement, designed to facilitate speedy exchange of reagents and fund collaborative research.

## ASTELLAS PHARMA INC.

Astellas has approximately 15,000 employees worldwide (www.astellas.com/en). With a strong track record of proven innovation and success, the organization pursues global leadership in the primary focus areas of immuno-oncology, targeted protein degradation, genetic regulation, blindness and regeneration. Our broader business focuses include oncology, immunology, muscle diseases, ophthalmology and other areas with high unmet medical needs.

We seek out partners who offer access to valuable resources, products, expertise and relationships that result in products which address unmet medical needs or provide significant improvements over existing therapies. We also seek out partnerships based on game-changing technologies that enable us to evolve ways of producing therapeutics such as peptides, nucleotides, proteins, genes, cells and other new modality-related therapeutics.

We have successfully partnered with key stakeholders at all levels, including entrepreneurial biotechnology and pharmaceutical companies, and government and academic laboratories. Our partnerships encompass global markets or select geographies in major or emerging markets. We have leveraged creative and flexible partnerships, as well as strategic acquisitions to drive us toward our goal of turning innovative science into meaningful value for patients.

For more information, visit:
www.astellas.com/en/partnering

## ASTEX PHARMACEUTICALS

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. We employ Pyramid™, our proprietary fragment-based drug discovery (FBDD) platform, to rapidly deliver high-quality drug leads with enhanced therapeutic potential across a wide variety of therapeutic targets. We use AI/ML to enhance our FBDD capabilities and have integrated cryo-EM technology into the platform to structurally interrogate biological targets previously not suitable for FBDD/SBDD including membrane targets.

We have a strong track record of successful drug discovery collaborations with both industry and academia. Astex is developing a proprietary pipeline of novel therapies and has multiple partnered products in clinical development under collaborations with leading pharmaceutical companies. Several compounds from drug discovery collaborations with Astex have been advanced by its pharma partners into clinical trials and onto the market.

Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan. Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

For more information about Astex Pharmaceuticals and Otsuka Pharmaceutical, please visit:
www.astx.com and www.otsuka.co.jp/en

## ASTRAZENECA

AstraZeneca

At AstraZeneca, we are a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Inspired by our values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.

Our scientists work in collaboration with others in dedicated laboratories in universities and research institutions, aiming to generate high impact science to support possible future advances in life-changing medicines.

The Discovery Centre (DISC) is our largest research centre in the UK, where more than 2,200 research scientists work across our therapy areas and drug discovery platforms. Located on the Cambridge Biomedical Campus (CBC) — Europe's leading centre for biomedical research — the DISC harnesses the power of our physical proximity to our neighbours across Cambridge, bringing together groups from the healthcare, academic, industry and research sectors to meet, collaborate and work together. Currently we're involved in over 200 partnerships across the Cambridge life sciences ecosystem and more than 130 active collaborations with the University of Cambridge.

To learn more, please visit astrazeneca.com and follow us on X/Twitter @AstraZeneca.

## BRISTOL MYERS SQUIBB

Bristol Myers Squibb™

At Bristol Myers Squibb, we are inspired by a single vision — transforming patients' lives through science. We focus on the science that drives meaningful change for patients, for their carers and loved ones, and for the communities and societies we share. We are a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, haematology, immunology, cardiovascular, fibrosis and neuroscience.

We are committed to continuing innovation and have a broad late-stage and robust early-stage pipelines, supported by our cutting edge technologies and discovery platforms. We are a global company, headquartered in the US, with industry-leading research and development, medicine development, delivery and commercial operations in the UK and Ireland.

In our facilities across the UK and Ireland, more than 900 members of Bristol Myers Squibb staff work to develop and deliver innovative medicines that transform people's lives.

Our values of passion, innovation, urgency, accountability, inclusion and integrity are central to who we are, what we do and how we do it. They inspire us every day and unite us with our colleagues and partners here in the UK and Ireland and around the world.

www.bms.com

## EISAI

Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. Everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in therapeutic areas with high unmet medical needs, including oncology and neurology.

Our External Innovation strategy aims to contribute to human health care by prioritising disease prevention, prediction, and treatment based on global investments and research collaboration. Our EMEA External Innovation team is located at the EMEA Knowledge Centre (EKC) in Hatfield, Eisai's regional headquarters. The site also houses neurology research laboratories and oncology and neurology clinical research as well as a secondary manufacturing facility. Our flexible approach allows us to engage in a number of different academic partnership models, including research sponsorship for specific programmes, joint research programmes, scientific start-up programmes, and 'Open Innovation' models involving public/private consortia.

Our mission is clear, we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy, in everything we do.

www.eisai.com

## ELI LILLY AND COMPANY

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Lilly External Innovation and Business Development teams are always on the lookout for the breakthrough ideas for novel therapeutics and partnerships that complement our internal pipeline. Working with Lilly means your team will have access to more than 6,000 scientists who are recognized worldwide for their deep expertise and advanced research capabilities. Our evaluation provides an independent, objective review of molecules, processes and technologies. To find out about our scientific areas of interest and how to collaborate with us please visit: www.lilly.co.uk/discovery/scientific-partnering

## FERRING PHARMACEUTICALS

Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X (Twitter).

## GSK

Innovation is at the heart of achieving our purpose — to unite science, talent and technology to get ahead of disease together. It's by discovering and developing new vaccines and medicines that we help patients and make a large-scale, positive impact on human health through prevention and treatment of disease.

To deliver transformational vaccines and medicines, our R&D approach is to focus on the science of the immune system, human genetics and advanced technologies, such as artificial intelligence and machine learning.

We prioritise research into vaccines and medicines across our four therapeutic areas of infectious diseases, HIV, oncology, and immunology including respiratory. We also remain open to opportunities outside these core areas where the science aligns with our strategic approach.

Through our own work, and partnerships with other businesses and academia, we currently have an innovative pipeline of 71 vaccines and specialty medicines based on the science of the immune system, many of which have the potential to be first or best-in-class. In all we do, we encourage our teams to pursue bold research, backed by data and science and underpinned by clear accountability.

www.gsk.com

## JOHNSON & JOHNSON INNOVATION

Johnson & Johnson Innovation works across the pharmaceutical and medical technology sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world.

We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies.

Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health.

Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

## MSD

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit: www.msd-uk.com

## PFIZER


At Pfizer, we are in relentless pursuit of scientific breakthroughs and revolutionary medicines that will create a healthier world for everyone. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of innovative medicines and vaccines. Pfizer colleagues work across developed and emerging markets each and every day to advance potential treatments that challenge some of the largest diseases of our time. Our core research areas of focus include oncology, internal medicine, inflammation & immunology, anti-infectives and vaccines. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. And, we regularly engage in collaborations with innovators to push forward great science – and continually seek new partners that are actively researching bold scientific ideas, capabilities and technologies that have the potential to bring innovative treatments to patients in need (www.Pfizer.com/partners). For more than 170 years, we have worked to make a difference for all who rely on us.

To learn more, please visit us on www.Pfizer.com and connect with us on X/Twitter, LinkedIn, YouTube and Facebook.

## SHIONOGI


Do you believe that your research has potential to deliver an innovation that improves healthcare and provides socio-economic impact beyond academia? If your answer is 'yes', Shionogi is here to work with you to realise the potential of your research.

Shionogi is a research-intensive global pharmaceutical company having its roots in Japan. The company's achievement in delivering many life-saving healthcare products stems from successful collaborations with partners in academic communities and biotech/pharma companies. As scientific research does not happen in isolation, Shionogi researchers pursue discovery through collaborations with scientists around the globe who share their passion in bringing innovations to the real world. Partnership with Shionogi involves working in a cross-cultural/international environment, setting research objectives with a view to therapeutic development, and building a shared commitment to deliver a win-win outcome.

Shionogi seeks research partners in its main therapeutic areas: infectious diseases and neuroscience (pain, psychiatric disorders, dementia, motor neuron diseases); additionally, in the area of vaccine R&D and related technologies, plus biomarkers, diagnostics and drug delivery technologies in these areas. Shionogi pursues research collaborations for drug modalities: nucleotide and peptide therapeutics, and technologies: AI-powered/data-driven drug discovery, digital health technologies, and medical devices. For detail, please see Shionogi's Wishlist (www.shionogi.com/global/en/innovation/randd/Wish_List.html).

Working together, we can deliver a significant impact on improving health and quality of life.

For more information about Shionogi, please visit: www.shionogi.com/global/en.

## TAKEDA

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

For more information, visit www.takeda.com.

## AFFILIATED COMPANIES

The Affiliated Company scheme, established in October 2016, now includes 78 organizations which bring diverse expertise and resource to the Milner network.


** Small and medium-sized enterprises*

***Start Codon portfolio companies ***Accelerate@Babraham companies*

# AFFILIATED COMPANIES



## ABCAM

progress happens together
abcam

At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That's why we're constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

**Contact:** www.abcam.com | researchareateam@abcam.com

## ABSELION

ABSELION

Discover the future of antibody and viral vector quantification with Abselion. Amperia, our newest product, is an innovative benchtop instrument that simplifies and accelerates titre measurements, enabling researchers to achieve accurate and efficient results in record time, directly from crude samples.

Amperia is based on a cutting-edge solid-state, all-electric detection principle that offers full automation and a compact footprint, making it the perfect solution for any lab.

**Contact:** www.abselion.com | info@abselion.com

## AGECURVE

AgeCurve specialises in tracking somatic mutation burden and building big evolutionary cell lineage trees from any kind of clonally related cell population. We combine genomics and transcriptomics information from the same cellular barcodes. Our Cell Tree Rings method provides a biological age estimation calibrated in healthy human blood samples and can be used in cell and gene therapy, drug safety/efficacy testing and precision medicine.

**Contact:** agecurve.co.uk | hello@agecurve.co.uk

## AIGENDRUG

AIGENDRUG, an AI drug discovery research company, provides a whole new way of exploring chemical, genetic, and disease space with cutting edge AI technologies. We launched our AI platform DrugVLAB v1 in April 2024, featuring ChemGen, ChemMining, ChemTox, ChemResponse, ChemTune, and ChemProtac. We are happy to discuss how these packages can be customized and used for your drug discovery projects.

**Contact:** www.aigendrug.com

## AI VIVO

**AI VIVO Organome Technology: Pioneering Organ Level Drug Discovery**

- AI VIVO developed the Organome Technology, a proprietary platform to capture the dynamic effect of diseases and treatments at the organ level, a paradigm shifting drug discovery.
- In contrast with target oriented drug discovery, using the organ level models (OrganoMaps) as a starting point of the discovery process greatly enhances the clinical predictability of novel compounds.
- The platform is empowered by proprietary generative AI capabilities for organ level modelling and novel drugs or biologics design.
- The platform has been validated in multiple disease areas by identifying candidates working in the clinic significantly faster and cheaper with an impressive high success rate.

**Organome Technology Applications**

- Organ level therapeutic discovery: Discover organ level disease mechanisms and identify corresponding novel therapeutic modalities.
- *In vivo* reprogramming therapies: Identify novel therapies by reprogramming specific cellular behaviour within an organ.
- Cell behaviour engineering and conversion: Identify novel mechanisms and modalities to engineer and convert one cell type/behaviour to another.

AI VIVO is advancing its internal pipeline in focus areas (fibrosis, skin, ageing, oncology) and looking to create value-adding partnerships that include joint development of organ level disease mechanisms and assets, *in vivo* cellular reprogramming therapies and cell engineering protocols.

**Contact:** www.aivivo.co | gifani@aivo.co

## ALLOY THERAPEUTICS

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, cell therapies, peptides, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat annual fee through Alloy's Innovation Subscriptions offering. As a reflection of their commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. Alloy is headquartered in Boston, MA, with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA.

**Contact:** alloytx.com/contact

## ALTEMIS LAB

AltemisLab

Founded by an experienced team with considerable industry knowledge. AltemisLab utilises this expertise to deliver the highest quality products and exceptional service, helping customers to map workflows and identify the tools that will realise practical, financial and time saving benefits.

The founders of AltemisLab have been working with 2D barcoded tubes since 2000, when this technology was first used by pharmaceutical companies for compound storage.

Using our knowledge and experience we have set out to perfect 2D tube design and we are proud to introduce our AlteTube range of sample storage tubes.

AltemisLab 2D barcoded tubes, barcode readers, de-capping, capping, and handling equipment symbolise a new era of efficiency. With AltemisLab you can rest assured that compliance, quality control and manufacturing excellence are unrivalled.

**Contact:** www.altemislab.com | info@altemislab.com

## ATHERNAL BIO***

Athernal Bio

Athernal Bio is developing new vaccines designed to lower the risk of cancer and other age-related diseases. Their approach focuses on targeting early indicators of cancer with novel vaccine techniques to eliminate them, aiming to improve patient outcomes.

****Accelerate@Babraham company*

## BIORELATE

Biorelate helps scientists in solving the most difficult biomedical challenges of today. We do this by curating truths from existing knowledge, enabling smarter and faster research & development. Galactic AI™ is the powerhouse behind Biorelate's suite of products and services, representing the pinnacle of data curation technology in the biopharmaceutical sector. This cloud-based supercomputing platform integrates state-of-the-art technologies, including Natural Language Processing (NLP), Artificial Intelligence (AI), and Large Language Models (LLMs), to deliver unparalleled data curation capabilities. Galactic AI™ revolutionises the way research questions are answered by illuminating the complex cause-and-effect relationships among genes, diseases, drugs, and various biological entities buried within the vast expanse of biomedical literature, alongside other more common research intelligence techniques. By leveraging the power of Galactic AI™, researchers can accelerate the pace of discovery and innovation in the biomedical field, leading to breakthroughs in understanding, preventing, and treating diseases.

**Contact:** www.biorelate.com | info@biorelate.com

## BIT.BIO

bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments. The company does this by industrialising the manufacture of human cells and making them more accessible.

bit.bio's opti-ox™ precision cell programming technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency. Our discovery platform extends this approach to any desired cell type by identifying the transcription factor combinations that define cell states (including identity, cell subtype identity, maturity) using high throughput screens and advanced data analysis.

The company has a cell therapy pipeline, based on txCells™, focused on serious diseases that lack effective treatments. The lead candidate, bbHEP01 based on txHepatocytes, is in development as a treatment for patients suffering from acute liver failure and acute-on-chronic liver failure. The ioCells™ research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines in research and drug discovery.

**Contact:** www.bit.bio

## BITFOUNT

Bitfount is a software platform for federated data science and AI, designed to enable data collaborations between multiple organisations without the need for data sharing. The platform can be used to train, deploy and validate AI models as well as to perform federated analytics, for applications including clinical trial acceleration, biomarker development, algorithm commercialisation, real-world evidence, basic research and more.

**Contact:** www.bitfount.com

## BIXBIO

bixbio is a biotechnology company working to unlock the potential of diverse genetic data in Africa to transform drug target discovery.

**Contact:** bixbio.com | info@bixbio.com

## CAERULEUS GENOMICS

caeruleus genomics

Caeruleus is a computational biotech company building an engine for functional cell profiling and novel target discovery. This includes a proprietary single-cell sequencing platform designed to enable accurate single-cell long-read sequencing at scale. The company's platform integrates wet lab and machine-learning capabilities to provide a functional and unbiased profile of complex ribonucleic acid (RNA) dysregulation across massive cell populations that allows them to profile and isolate rare cell types and discover novel, difficult-to-find or previously undruggable therapeutic targets. This enables them to thereby discover more effective therapies and partner with companies active in targeted immunotherapies and genetic medicines across various diseases.

**Contact:** www.caeruleus.bio | info@caeruleus.bio

## CAMENA BIOSCIENCE

camena
BIOSCIENCE

Camena Bioscience is a synthetic biology company. The company's pioneering platform gSynth® is a wholly novel multi-enzymatic DNA synthesis technology which addresses the challenges of generating long and complex genes.

Enzymatic-based DNA synthesis methods have gained traction in recent years as pharmaceutical companies have sought solutions to the limitations of traditional methods, but until now an accurate and high-throughput alternative has been unavailable. Enabling researchers to "write" DNA with the same confidence and ease with which they can "read" DNA provides access to gene sequences previously unobtainable, accelerating discovery timelines and development of new therapeutics.

Traditional methods of DNA synthesis also produce significant organic solvent waste. As the focus on sustainability becomes more acute and with Pharma's collective commitment to decarbonising health systems, Camena is leading the way with a green synthesis technology focused on reducing waste.

**Contact:** camenabio.com | info@camenabio.com

## CARDIATEC BIOSCIENCES

CardiaTec is a TechBio company employing computational methods to decode the biology behind cardiovascular disease. The company leverages large and high-dimensional human multi-omics data to better navigate complex disease biology to identify novel and differentiated therapeutics.

CardiaTec has built the largest proprietary human heart tissue multi-omics dataset and has access to 65 hospitals for whole human heart procurement, with paired electronic health records and blood samples.

The company spun out of the Han Lab at the Milner Therapeutics Institute, University of Cambridge, and has brought together industry experts from leading organisations including Bristol Myers Squibb, Cleveland Clinic and Recursion Pharmaceuticals.

**Contact:** www.cardiatec.ai | info@cardiatec.ai

## CELL GUIDANCE SYSTEMS

Our innovative printable PODS growth factors, conventional growth factors, and small molecules serve to guide and support cells. Our wide range of surfaces and extracellular matrix products, including Softwell and the versatile PeptiGel self-assembling peptide hydrogels (SAPHs) enable more challenging cell culture. Our highly-cited karyotyping service ensures the integrity of your cell-based work. For exosomes and other EV research, Cell Guidance Systems products and services enable the purification and subsequent analysis.

**Contact:** www.cellgs.com | info@cellgs.com

## CEREVANCE

Cerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia and amyotrophic lateral sclerosis. Utilizing a large and growing repository of over 15,000 human brain tissue samples, Cerevance is generating an unprecedented level of expression and epigenetic data thereby enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and advanced machine learning techniques to uncover the gene expression profiles of select cell types to identify novel targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states. With the information obtained from its research, combined with the expertise of its team of scientists and drug developers, Cerevance is advancing multiple therapeutics through clinical development, with CVN424, CVN766, and CVN293 being the furthest along in the pipeline. CVN424 is a first-in-class non-dopamine therapy that shows promise in improving both motor and non-motor symptoms of Parkinson's disease and may also have disease-delaying effects. CVN766 is a potent and highly selective antagonist of the orexin 1 receptor which may benefit various psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome. CVN293 is a novel blocker of potassium efflux in glia, regulating the inflammasome in individuals living with neurodegenerative diseases.

**Contact:** cerevance.com
| Johnna Simoes ir@cerevance.com

## CRESSET

Chemists in the world's leading research organizations use Cresset solutions to discover, design, optimize, synthesize and track the best small molecules. By integrating their *in silico* CADD and design-make-test-analyze discovery solutions with Cresset's first-class discovery research resources, researchers will have access to patented CADD software, collaborative Torx® DMTA platform and expert Discovery CRO scientists. In helping organizations reach better design and synthesis decisions faster and more efficiently, we enable them to win the race to success in industries including: pharmaceuticals, agrochemicals, flavours and fragrances.

**Contact:** cresset-group.com
| enquiries@cresset-group.com

## CUMULUS ONCOLOGY

Cumulus Oncology connects the dots between oncology research, drug discovery, development, commercialisation and value creation to accelerate drug development programs, create new companies, and co-develop or license attractive assets/targets in oncology. Cumulus works with asset holders from various backgrounds (both academic and commercial) to ensure the best science is moved forward effectively. We use a 'one team – multiple companies/projects' approach, enabling through a highly efficient deployment of resources and capital.

**Contact:** cumulusoncology.com

## CYTIVA

Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020. Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes. Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

**Contact:** www.cytiva.com
| Devina Divekar – devina.divekar@cytivalifesciences.com

## DOMAINEX

Domainex
Enrich your medicines pipeline

Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.

Domainex provides innovative and customised biology and chemistry services for instance to advance disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression of drug discovery research towards patients. Domainex's innovative science and extensive technical capabilities enable it to produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing intellectual input, know-how and a wealth of experience to bear on drug discovery research projects.

Domainex's highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on numerous patent applications of candidate drugs. The company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.

**Contact:** www.domainex.co.uk | enquiries@domainex.co.uk

## ENHANC3D GENOMICS

ENHANC3D GENOMICS

Enhanc3D Genomics ("Enhanc3D") is a private functional genomics company based in Cambridge, UK. Enhanc3D was founded in 2020 out of Professor Peter Fraser's research laboratory at the Babraham Institute and is backed by Bioqube Ventures, Start Codon and private investors.

The company is developing a platform to unlock the full potential of the three-dimensional organisation of the human genome. Using AI technology, Enhanc3D's proprietary platform directly measures DNA interactions controlling gene regulation. This focuses on the uncharted non-coding regions that make up 98% of the human genome with the aim to identify disease-associated genetic interactions including those that are causal for disease susceptibility and progression. This unique and innovative approach has the potential to transform traditional target discovery methods and make precision medicine an everyday reality for patients. Enhanc3D is led by a team which combines deep technology and therapeutics expertise, with strong operational and commercial experience and is supported by a strong scientific advisory board and founders.

**Contact:** enhanc3dgenomics.com | info@enhanc3dgenomics.com

## EPHYRA***

Ephyra is an RNA therapeutics platform company focused on the development of proprietary sponge RNAs to treat disease.

Due to recent advances in the design, manufacture and targeted delivery of nucleic acids, RNA-based therapeutics are rapidly becoming a mainstream drug modality. However, broad clinical adoption of microRNA (miRNA)-targeted therapeutics has historically been hampered by a conventional "one drug, one target" approach and costly chemical modifications that are unnatural and non-biodegradable leading to toxicity.

Sponge RNAs are naturally occurring molecules carrying multiple, tandem binding sites, known to bind and competitively inhibit small regulatory RNAs and their downstream gene pathways. Based on their ability to fine-tune gene expression by modulating regulatory inputs, physiological sponge RNAs provide an attractive basis for constructing designer sponges for therapeutic application.

Ephyra's enhanced sponge technology has potential for different target types and broad applicability across multiple therapeutic areas. Our first-generation molecules target miRNAs to restore cellular health to treat disease. Ephyra's proprietary platform engineers unique sponge RNAs with novel structures optimised for versatility, specificity, efficacy, and modularity. The company is developing a pipeline of drugs for clinical indications and is seeking strategic partners and investors.

**Contact:** www.ephyra.bio | info@ephyra.bio

## EREBAGEN

Erebagen is a synthetic biology company that discovers, optimises and scales truly novel bioactive products from microbes by activating previously silent biosynthetic gene clusters; we will harness data driven automation and machine intelligence to unlock the potential of bacteria, nature's greatest innovators.

Microbial bioactives are a successful class of compounds that evolved to be advantageous over millions of years. They make up 49% of all marketed medicines, with applications in human health, agriculture and industrial biotech – markets with substantial unmet needs. The costs of genome sequencing have decreased 600-fold, providing plenty of targets, with the bottleneck being the ability to identify new effective leads.

In the lab >80% of the biosynthetic pathways for microbial bioactives are switched off. Erebagen targets these silent pathways switching on and modifying the novel compounds discovered. The bacteria are used to perform structural diversity work, applying proprietary biosynthetic engineering tools, a process now part-automated.

With a first partnership secured, Erebagen's business strategy is to invest in its technology platform while advancing products through partnerships. The company is seeking investment to hit key milestones to fully automate the platform, expand characterised libraries, apply AI and ML and secure further partnerships, positioning Erebagen for successful strategic development.

**Contact:** erebagen.com | info@erebagen.com

****Accelerate@Babraham company*

## GENEDATA


For the last 25 years, Genedata has been transforming life science data into intelligence with a portfolio of award-winning software solutions and scientific consulting. Our Biopharma Platform of advanced software are built on open, enterprise-level client-server architecture, which can be deployed to a variety of infrastructures, including on-premises or cloud-based installations. We provide digital solutions to cover your data analysis needs, from mass spectrometry biotherapeutic characterization (Expressionist), AI powered high content screening analysis (Imagence) to the capture & analysis of high throughput screens (Screener) and managing your NGS workflows from cell line development to biosafety (Selector). We also support the digitalization of your company-wide R&D processes with our flexible workflow solutions, to transform your biotherapeutic discovery (Biologics), breakdown data silos by integrating multi-omics, biomarker, and clinical data (Profiler) and design next-generation manufacturing processes for cell line development, upstream and downstream processing, formulation, and analytics (Bioprocess). We also offer a range of services and support, from installation and customization to global roll-out support, training, data analysis, application consulting and IT consulting services, all tailored to clients' specific needs. Our highly skilled professionals bring extensive domain knowledge and experience to your organization. Today, we work with the world's leading pharmaceutical, agrochemical, and biotechnology companies, as well as some of the most innovative life science research institutions.

**Contact:** www.genedata.com
| www.genedata.com/company/contact-us

## GENSCRIPT


GenScript is the world's leading technology and service provider of life science R&D and manufacturing, founded in 2002 as one of the first commercialised gene synthesis providers. GenScript provides life sciences services and products to over 200,000 scientists in over 200 countries worldwide, including custom peptide synthesis, complex protein expression and engineering, custom antibody development and engineering, *in vitro*/*in vivo* pharmacology, as well as a variety of other research-focused catalogue products.

After almost two decades of rapid growth, the company has expanded its business in recent years into the fields of immunotherapy, CDMO and microbiology to further its core mission of making people and nature healthier through biotechnological innovation. With global support for its loyal customers and over 5000 employees located across the globe and dedicated sites in the Netherlands and the UK, GenScript continues to strive towards its vision of being the most reliable biotech company in the world, in service of a better and healthier future.

**Contact:** www.genscript.com

## HEALX

Healx is a mission-driven biotech, pioneering the next wave of drug discovery by re-engineering the entire process from the ground up. At the core of our approach is Healnet, the next generation AI platform we built to attack the drug discovery problem in a massively parallel, hypothesis-free way.

We deploy Healnet across three core areas: drug redevelopment, combination therapy development, and molecular enhancement. In each of these areas, Healnet uses cutting-edge AI to rapidly discover novel disease biology and modes of action — without being limited to a single target — and identify non-obvious connections between that biology and existing compounds. Our team then applies their drug discovery and development expertise to accelerate these novel treatment opportunities towards the clinic.

**Contact:** www.healx.io | clara.tang@healx.io

## IGNOTA LABS

Each year, the pharmaceutical industry abandons hundreds of drug projects due to safety concerns revealed during pre-clinical or Phase I trials. These trials often highlight safety issues without explaining their causes or suggesting mitigation strategies. Ignota Labs addresses this critical gap with its advanced causal artificial intelligence (AI) platform SAFEPATH.

SAFEPATH uses causal AI to uncover the underlying mechanisms of drug-induced toxicities. By combining cheminformatics, bioinformatics, deep learning, and proprietary datasets. This allows Ignota Labs to propagate from chemical structure to drug:protein, protein:protein, protein:pathway etc. interactions to uncover the mechanism between chemical structure and clinical output. SAFEPATH goes beyond predicting safety issues to offering actionable solutions.

This platform has facilitated collaborations with industry leaders like The Broad Institute, and Wellcome Trust for Mitochondrial Disease Research and various biotech partners as clients. We have validated this platform in several different ways, from derisking drug discovery projects through proactive assessment of *in vitro* toxicity, to uncovering the mechanism of drugs that have caused drug induced liver injury for 20 years without adequate explanation.

This culminates in an entirely new dimension on how toxic compounds are handled, facilitating Ignota Labs to either partner with companies with distressed assets, or in-licence those assets and share the upside of the revitalised new drug.

**Contact:** ignotalabs.ai | hello@ignotalabs.ai

## INTELLEGENS

intellegens

Intellegens software applies advanced machine learning to accelerate innovation for life sciences, chemicals, and manufacturing applications. In the race to design and deliver new and improved therapeutics, it is essential to maximise value from the existing data available to an R&D organisation. That data may come from experiment, simulation, trials, or patient populations. It is typically sparse (i.e., not every possible attribute is populated) and noisy – features that cause conventional machine learning methods to fail.

The Alchemite™ machine learning software is a unique technology, originating at the University of Cambridge, that enables users to build machine learning models from sparse, noisy data. These models can then be used to direct experimental programs along the most productive pathways and to gain breakthrough insights into which factors drive key properties for drugs and biopharmaceuticals. Successes have included identifying potential drug candidate compounds, significantly reducing the amount of experimentation required to achieve development objectives, and providing valuable insights into large-scale commercial pharmaceutical datasets.

**Contact:** www.intellegens.com | info@intellegens.com

## ISOGENICA


Isogenica develops highly versatile, small-format VHH antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation, and other serious diseases.

VHH can be assembled to create multi-specific biotherapeutics or used to achieve targeted drug delivery as components of ADCs and cell therapies including CAR-Ts.

We are leaders in antibody discovery and engineering. Drawing on our 20 years of expertise and knowledge, we have built a unique and proven engine for biotherapeutic development and our own deep pipeline including two clinical stage assets.

**Contact:** isogenica.com | info@isogenica.com

## JW PHARMACEUTICAL

Taking the first step in 1945, JW Pharmaceutical has found the market for domestic therapeutic drugs based on its philosophy of respecting life and pioneering spirit. JW Pharmaceutical established a comprehensive research center in 1983 based on accumulated technology and outstanding capability. Based on a long history and know-how in treatment and medicine, JW Pharmaceutical are constantly researching and developing innovative new medicine. We are targeting the diseases with high demand for medical unmet needs, concentrating on the development of innovative new medicines using JW's unique technology, and conducting research activities in line with global trends through open innovation. Research directions are Innovation R&D, Nutrition Therapy and Diagnostics. 22 pipelines are developing, in disease areas including cancer, immunological disease, cardiovascular system, metabolic disease, regenerative medicine, rare and eye disease. We are committed to making our society bright and healthy by producing and supplying innovative technologies, products and services which will support healthy lives, and will pursue the satisfaction and happiness of customers, shareholders and the employees through our trustworthy activities.

**Contact:** www.jw-pharma.co.kr
| Kyoung-Wan Cho – kwcho@jw-pharma.co.kr

## LIFEBIT

Lifebit is democratising access and understanding of genomic data to leap-forward cures and disease prevention. Lifebit solves the challenge of analysing vast amounts of distributed and previously inaccessible genomics data. We do this with an end-to-end platform that enables federated analysis and powerful automation, no matter where data resides, no matter what compute infrastructure is employed.

Lifebit CloudOS is the first fully federated clinico-genomic data platform that integrates and accommodates all best practices and compliance models. Data privacy and security are always assured and collaboration across teams is seamless. Importantly, with its federated architecture, organisations and researchers are not required to move sensitive data from one place to another, enabling secure, collaborative access.

Whether drug discovery, diagnostics or predicting drug response, Lifebit's technology creates new collective understandings from complex distributed data. With our partners and customers, we are shaping an integrated, collaborative landscape of knowledge to enrich life and enable tangible breakthroughs.

**Contact:** www.lifebit.ai | hello@lifebit.ai

## MAXCYTE

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialisation of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class electroporation technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For 25 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today's process to innovate tomorrow's solutions. Let's Build Better Cells Together.

**Contact:** www.maxcyte.com

## MEDANNEX

Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.

Following a Series B fundraise, and supported by both Scottish Enterprise and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.

Having completed pivotal toxicology studies and cGMP manufacturing of our lead candidate 'MDX-124', we recently initiated the First-in-Human clinical study, in oncology. MDX-124 is the first monoclonal antibody to target annexin-A1, a protein in the immune system that plays a key role in inflammation and the development of numerous cancers, autoimmune conditions and other diseases. Our non-clinical therapeutic development programme for autoimmune diseases continues in parallel.

**Contact:** www.medannex.org | info@medannex.org

## MICROBIOTICA

The microbiome is transforming our knowledge of biology and promising novel therapies for a wide range of diseases based on live bacteria. Microbiotica is a pioneer translating new rigour in microbiome science to enable it to fulfil its promise as a new therapeutic modality. Recognition of this has been demonstrated by collaborations with Cancer Research UK, University of Cambridge, University of Adelaide and Genentech, by multiple awards, and by a recent £50m fundraise supported by an international syndicate of investors. This enables the company to transition into the clinic and expand its discovery pipeline.

The company's unique platform was initially built on investment over 10 years at the Wellcome Sanger Institute that addressed fundamental barriers in microbiome genomics, mass gut bacterial isolation, patient microbiome profiling, and identification of therapeutic bacteria. These capabilities have been industrialised and set the company apart, enabling a precision medicine approach to the microbiome by identification of clinical bacterial signatures that serve as stratification biomarkers and live bacterial therapies.

Microbiotica's therapeutic focus is immuno-oncology and IBD where two exciting assets, MB097 and MB310, are progressing into clinical trials. The company has an ongoing strategic commitment to the microbiome in immuno-oncology driven by MITRE clinical collaboration in multiple cancers with Cambridge University Hospitals and CRUK. Programs in additional therapeutic areas are being progressed in the Discovery phase.

**Contact:** www.microbiotica.com | info@microbiotica.com

## NAVINCI DIAGNOSTICS

Navinci Diagnostics is a Swedish biotechnology company specializing in developing innovative solutions for studying protein interactions. With a focus and strong legacy in developing in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.

**Contact:** navinci.se | contact@navinci.se

## NEW PLATELET COMPANY***

New Platelet Company
NewPltCo

Blood platelets stop bleeding after injury. When the platelet count is low, for example as a result of cancer treatment, patients are given platelet transfusions collected from donors to prevent bleeding. However, there is no unlimited safe supply of platelets for all and at a time of a natural disaster, a nuclear event, war, or a pandemic, stocks can drop dangerously low. To add to the supply of human donors, the New Platelet Company manufactures platelets from induced pluripotent stem cells (iPSCs).

**Contact:** m.r.tijssen@gmail.com

## OLINK

Olink

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to developing our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.

Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.

**Contact:** www.olink.com

****Accelerate@Babraham company*

## OMICSCHART

OMICSCHART

OmicsChart is a computational cancer biology startup developing a multi-omics cancer biomarker discovery platform specifically designed for translational researchers. These teams often face significant delays — sometimes extending to months — when trying to obtain biological evidence crucial for clinical drug development, largely due to challenges such as accessing fragmented data, navigating complex analytics, and dealing with costly proprietary data licensing agreements.

OmicsChart platform is designed to streamline this process, enabling translational cancer scientists to rapidly test hypotheses and extract insights from a harmonised mix of public, proprietary, and in-house biomarker data with just a few clicks. Built on federated data integration and domain-driven ML/AI, the platform features biologist-friendly scientific visualisations and significantly reduces the time required for data acquisition and analysis — by 150 times compared to current practices. It provides comprehensive insights on DNA and RNA biomarkers, immune cell composition, and single-cell tumour resolution, all integrated with clinical information across 35 cancer types.

Currently serving numerous clients in the pharmaceutical industry, OmicsChart is backed by industry leaders such as the Debiopharm Innovation Fund and Techstars, positioning it as a valuable partner for advancing pharmaceutical research and development.

**Contact:** www.omicschart.com | info@omicschart.com

## ONCIMMUNE

Oncimmune®

Oncimmune is a leading autoantibody profiling company that enables precision medicine, focusing on the rapidly growing fields of immuno-oncology, autoimmune diseases, infectious diseases, and longevity. By partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs), Oncimmune discovers novel biomarkers to develop targeted and effective therapies for immune-mediated diseases. Autoantibodies, which mistakenly target the body's own proteins, offer insights into the immune system's role in various diseases. Our ImmunoINSIGHTS™ platform converts these autoantibodies into actionable biomarkers, aiding in early disease detection and predicting immune-related adverse events (irAEs).

Supported by a vast antigen library of over 9,000 antigens, our technology is used for early-stage discovery, mechanism of action validation, patient stratification in clinical trials, and developing companion diagnostics. Our mission is to enable precision medicine by helping partners discover novel biomarkers and predict treatment efficacy, leveraging our scientific expertise and advanced technology to enhance patient outcomes and advance the field of precision medicine.

**Contact:** oncimmune.com | info@oncimmune.com

## OPPILOTECH

Oppilotech modelling methodology is different from traditional approaches (Flux Based Analysis) in that we go into a much higher level of detail incorporating parameters such as catalytic rates, metabolite levels and half-lives. The high level of detail allows us to reveal new biology and identify first-in-class non-intuitive drug targets. We initially focused our modelling efforts on *E.coli* identifying four first-in-class antibacterial drug targets and generated active chemical matter against three of them. The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells, allowing us to address a wider range of diseases.

Oppilotech is actively seeking partnerships with pharma/biotechs/academic groups to model specific biological pathways to identify viable drug targets and new biology.

**Contact:** www.oppilotech.com

## PELAGO BIOSCIENCE

Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical drug discovery and development with our expertise in biologically relevant assay systems. Our unique core technology, the Cellular Thermal Shift Assay (CETSA® by Pelago Bioscience), has multiple assay formats that make it a keystone of decision-making throughout the drug discovery pipeline. We offer a range of customized services, from confirming target engagement to strengthening target validation and understanding the mechanism of action of your compounds. Our approach is designed to help you make better decisions faster, no matter where you are in the drug discovery process.

**Contact:** www.pelagobio.com | contact@pelagobio.com

## PHARMENABLE THERAPEUTICS

PharmEnable Therapeutics is a drug discovery company accessing the inaccessible by reimagining small molecules through AI. We develop innovative drugs against targets that require the specificity of biologics, but that cannot be addressed by them due to physical access barriers.

With our proprietary AI-enabled platform chemSEEK, we map unexplored chemical space specific for the target of interest to discover diverse and 3-dimensional small molecules. Our interdisciplinary approach integrates advanced medicinal chemistry expertise and cutting-edge computational methods to deliver novel therapeutics with exquisite specificity and selectivity.

We are a therapeutics company with a discovery stage pipeline in oncology and neurology. Our lead programme is a highly selective dual inhibitor to treat ovarian cancer. Our platform is target-agnostic, and we also engage in partnerships across disease areas where achieving drug selectivity and optimal properties poses a significant challenge.

We are VC backed by MP Healthcare Venture Management (the venture arm of Mitsubishi Tanabe Pharma Group) and have ongoing collaborations with pharma and biotech companies including Nxera (formerly Sosei Heptares).

**Contact:** pharmenabletx.com
| Jessica Iegre – jessica.iegre@pharmenabletx.com

## PHARMIDEX

Pharmidex is a UK-based contract research organisation, founded in 2002, providing high quality, cost-effective and rapid solutions to clients. Our services include *in vitro* ADME, drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP, GLP/GCP), toxicology (non-GLP, GLP) and histology/clinical chemistry/ haematology. Pharmidex also offers *in silico* modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune and metabolic disease programmes.

The Pharmidex scientific team (45% PhD and 35% MSc qualified) is highly experienced in designing, executing, reporting, and discussing results of studies to help advance client projects successfully.

Working with 250+ global clients, including medical charities, academic groups, biotech and pharma, we have undertaken greater than 15000 studies. In addition to our fee-for-service offering, Pharmidex is always seeking opportunities to collaborate in grant funded projects. We have successfully participated in 30+ collaborative grant funded projects to date.

**Contact:** pharmidex.com | bd@pharmidex.com

## PHOREMOST

PHOREMOST

PhoreMost is a Cambridge UK-based biotech company, focused on its core goal of "Drugging the Undruggable™".

Founded in 2014, PhoreMost has developed its proprietary next-generation phenotypic screening platform SITESEEKER® which can discern the best new targets for future therapeutics and, crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other diseases of unmet need.

PhoreMost's internal pipeline focusses on targeted protein degradation (TPD), and oncology. In the TPD space, PhoreMost has been able to progress small molecule binders to multiple novel E3 ligases and has developed its screening approach to allow the identification and exploitation of target- and disease-selective E3 ligases. More recently the pipeline has been used to identify a molecular glue type mechanism, via our GlueSEEKER® iteration of the platform.

In addition to internal programmes, PhoreMost collaborates with a range of pharma and biotech partners to enable access to its SITESEEKER® platform. Through these collaborations — with companies including Boehringer Ingelheim and Roche — PhoreMost works closely with its partners to screen pathways of interest and deliver validated targets with functional, binding peptides, suitable for entry into the drug discovery pipeline.

**Contact:** www.phoremost.com | info@phoremost.com

## PRECISIONLIFE

precisionlife
improving health | for everyone

PrecisionLife is a pioneering precision medicine company expanding the field beyond oncology and rare disease with its focus on complex chronic diseases, including CNS, autoimmune, cardiovascular, respiratory, and metabolic diseases to find better treatment options for patients with unmet medical needs.

We improve the probability of success in every stage of biopharma innovation with our unparalleled understanding of causal biology and unique ability to stratify patients into clinically relevant subgroups and link them to effective targets and treatments by the molecular mechanism of either their disease or drug response.

Our insights enable us and our biopharma partners to:

- De-risk target selection with mechanism-based patient stratification biomarkers linking targets to patients, identify novel treatment opportunities for unmet medical needs
- Design targeted clinical trials that are easier to recruit, faster to readout, and more likely to succeed
- Find new indications and out-licensing opportunities for an existing drug program
- Develop highly predictive complementary diagnostics, personalized risk prediction and disease prevention tools.

We're working in collaboration with some of the largest global biopharma companies and have a proven, responsive, and cost-effective way of contracting and working with our partners.

**Contact:** precisionlife.com | info@precisionlife.com

## QKINE

Qkine

Qkine manufactures high-purity, animal-free growth factors, cytokines and other complex proteins for life science applications including stem cell and organoid culture. Based in Cambridge, UK, with an established global distribution network, Qkine combines proprietary production processes with protein engineering technology to tackle fundamental biological and scale-up challenges. Our goal is to provide the highest purity, bioactive proteins to best support our customers and maximize the impact of their science.

As leaders in protein innovation, approximately 30% of our catalogue is formed of unique products including pioneering growth factor forms for scaling organoid cultures. Our product range spans a wide range of applications including hepatocyte, cardiac and neural differentiation, all aimed at increasing reproducibility in your research.

Qkine is an ISO9001: 2015 certified company and we can support scale-up and commercial manufacturing by offering lot reservations, bulk orders, custom vialling, and custom QA.

**Contact:** www.qkine.com | info@qkine.com

## QUREIGHT

Qureight.

Founded in 2018, Qureight is a Cambridge, UK-based medical data company working to transform outcomes for people with complex diseases. Their proprietary digital infrastructure houses and curates multiple types of data for powerful algorithmic analysis, the results of which can be used to direct complex disease drug development and to evaluate the efficacy of existing treatments. They work in partnership with a number of hospitals in the UK and globally as well as with multiple biopharma partners to advance new medicines in diseases like lung fibrosis by helping clinical trials become smarter, faster and cheaper.

**Contact:** www.qureight.com
| Muhunthan Thillai – m.thillai@qureight.com

## SAI LIFE SCIENCES

Sai Life Sciences is one of India's fastest growing Contract Research, Development & Manufacturing Organizations. A pure-play, full-service CRO-CDMO, it works with global innovator pharma and biotech companies to accelerate the discovery, development and commercialisation of small molecules.

Over two decades, Sai Life Sciences has served a diverse set of NCE development programmes, consistently delivering value based on its quality and responsiveness. It has a 100% successful track record of regulatory inspections across its R&D and manufacturing facilities. Today, it works with 17 of the top 25 large pharma companies, in addition to multiple small and mid-sized pharma & biotech companies and has over 2200 employees across its facilities in India, UK and USA.

In 2019, Sai committed to investing over US$150M between 2019 and 2023 to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

The company's infrastructure expansion includes:

- Discovery biology lab in Boston, USA
- Centre of excellence in process R&D in Manchester, UK
- Integrated Discovery Services in Hyderabad that include medicinal chemistry, *in vitro* and *in vivo* biology services, DMPK, toxicology and a vivarium
- 172 KL API & Intermediate manufacturing capacity
- High potent capability in R&D and manufacturing
- Dedicated clean room block
- Dedicated Amidites block

**Contact:** www.sailife.com
| Victoria Steadman – victoria.s@sailife.com

## SCALE BIOSCIENCES

Scale Biosciences is at the forefront of a new era in single cell research, providing scientists with the tools they need to push the boundaries of biological discovery. Our innovative platforms combine accessibility, flexibility, and scalability, allowing researchers to design experiments that fit their unique scientific objectives without compromising on quality or results. By enabling the analysis of up to millions of cells and the multiplexing of hundreds of samples, Scale Bio empowers scientists to generate rich, comprehensive datasets that can unlock new insights into complex biological systems. We are dedicated to collaborating with the scientific community to drive innovation and accelerate breakthroughs in single cell-omics. Join Scale Bio on this transformative journey and help unleash the full potential of single cell research today.

**Contact:** scale.bio | info@scale.bio

## SELLECK CHEMICALS

Selleck Chemicals are the second-largest biocompound vendor in the world and specialize in inhibitors for *in vivo* and *in vitro* application, compound libraries, therapeutics and *in vivo* antibodies, and bioreagents. Their products have been cited in numerous publications and have been trusted by researchers around the globe.

**Contact:** selleckchem.com

## SELVITA

Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.

The company was established in 2007 and currently employs over 1000 scientists, with >40% Ph.D. level scientists. The research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia. Our international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.

Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases, and CNS.

The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of drug discovery processes from *in silico* drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical *in vitro* and *in vivo* pharmacology, structural biology, all tailored to the customer's needs.

**Contact:** selvita.com | selvita@selvita.com

## SEMARION

Semarion is a seed-stage technology company with a mission to accelerate the pace of drug discovery. We are rethinking adherent cell assays to produce better drug data, faster. Our proprietary SemaCyte® microcarrier platform leverages novel materials physics to move and barcode adherent cells. Our approach introduces flexibility, miniaturisation, and multiplexing into existing drug discovery tools and workflows.

**Contact:** www.semarion.com | info@semarion.com

## SENGENICS

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.

Our novel seromics technologies drive the creation of protein microarray services and products for autoantibody biomarker profiling. Our focus is helping advance the discovery, validation, and use of biomarkers in the fields of autoimmune disease, immuno-oncology, neurological and infectious disease.

Sengenics was founded in 2008, built on technology developed at Cambridge University. Our KREX protein folding technology ensures that the proteins on our arrays are correctly folded, full length and functional. This is critical for autoantibody discovery because over 90% of antibodies recognize the shape of an epitope, not the amino acid sequence.

We work with many of the world's top pharmaceutical companies as well as biopharma, academic institutions, contract research organizations and disease foundations. More than 160 companies and institutions have used our platform to advance their research and biomarker development.

**Contact:** www.sengenics.com | enquires@sengenics.com

## STEMBOND TECHNOLOGIES

StemBond Technologies

StemBond Technologies is working toward a future where cell-based medicine is effective, cheap, and globally available.

Why is this not today's reality? The critical reason is how cells from *in vivo* are cultured *in vitro*. It is an issue across life sciences; many cells taken from an organism quickly suffer from loss of function, phenotypic drift, and cell death when cultured in laboratories.

Researchers have typically focused on creating cocktails of media conditions to force cells to behave a certain way. However, we now know that 'biochemical' conditions are only half the equation for controlling cell function.

To gain greater control over cell fate and function *in vitro*, cells must physically 'feel' like they are in the environment that supports a given behaviour. This requires control over the 'biomechanical' environment.

StemBond Technologies are leveraging advanced materials science to harness cell fate and function through the biomechanical environment. We have the tools and methods to provide biomechanical cell culture platforms to support cells in a desired function. With this, we will develop and partner to produce higher quality and scalable cell-based therapeutics.

**Contact:** www.stembond.tech

## STEMCELL TECHNOLOGIES

STEMCELL™ TECHNOLOGIES

STEMCELL Technologies are dedicated to improving lives by advancing knowledge and scientific discovery, fostering inclusion in science, technology, engineering, and mathematics (STEM), and investing in sustainability and corporate social responsibility. The company provides over 2,500 high-quality cell culture media, cell separation technologies, instruments, accessory products, and services to scientists around the world working on stem cell, immunology, cancer, regenerative medicine, and cellular therapy research. As Canada's largest biotechnology company, STEMCELL employs more than 2,400 people globally.

**Contact:** www.stemcell.com

## STORM THERAPEUTICS

STORM Therapeutics (STORM) is a clinical stage biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.

STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases.

The pipeline is exemplified by STORM's METTL3 inhibitor (STC-15) which has received IND approval and commenced its Phase 1 clinical study in cancer patients in 2022. STC-15 represents the first ever RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional programs are planned for advancement into IND-track activities in 2023.

STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company's proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.

**Contact:** www.stormtherapeutics.com | info@stormtherapeutics.com

## STRATOSVIR

Stratosvir is a UK-based early stage company engineering viruses to treat solid tumours. Viral immunotherapy is a new modality and has shown promise in the clinic but still requires direct injection intra-tumourally which limits its use and market (e.g. Imlygic for use for inoperable melanoma). Stratosvir is engineering the viruses for intravenous injection to overcome this barrier and bring the modality into the mainstream.

Stratosvir's viral immunotherapy platform is designed to act multi-modally to turn unresponsive immunologically "cold" tumours "hot". This will benefit patients that do not respond to current immunotherapies, such as prostate cancer patients.

Advanced prostate cancer is a significant unmet need. Many prostate cancer patients that are diagnosed early will survive on androgen blockade treatment for years but when resistance occurs, or when diagnosed at a late stage, sufferers have few options with a poor quality of life. Stratosvir will engineer viruses that carry anticancer payloads for prostate and other cancers of unmet need.

**Contact:** stratosvir.com | mission.control@stratosvir.com

## SULANTRIX

Sulatntrix span out from the University of Liverpool in 2022 and is now based in Liverpool and Cambridge, UK. The business is working on new medicines for patients suffering from tumours where treatment options aren't available, or where existing medicines have stopped working. Led by Pharma industry veteran David Williams and Patrick Eyers, Professor of Cell Signalling at the Institute of Systems, Molecular and Integrative Biology, the Sulantrix team is exploring innovative medicines targeting cancer, focusing on a class of proteins known as pseudokinases.

**Contact:** sulantrix.com

## SYNEXA LIFE SCIENCES

Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays. With a team of 150 across five global laboratory locations; Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA), we provide innovative solutions to support our customers to achieve their clinical milestones. Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and our ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and ultimately better management and treatment of human health.

Synexa, improving the quality of human health through innovative biomarker and bioanalytical solutions.

**Contact:** www.synexagroup.com | contactus@synexagroup.com

## TAGOMICS

Tagomics have developed a ground-breaking, multi-omic, biomarker discovery platform which offers a step change in the development of genomics-based diagnostic assays. The company is a spin-out from the University of Birmingham (UoB), founded by Dr Jack Kennefick (CEO) and Dr Robert Neely (CSO). The company is a graduate of the Cambridge-based venture building programme, Start Codon, and is backed by Start Codon, IQ Capital, UoB, and Innovate UK.

Tagomics' platform and advanced machine learning pipeline offers simple and streamlined access to multi-omic biomarkers. The approach is epigenetics driven, offering selective tagging, enrichment, and sequencing of the active (unmethylated) regions of the genome. The method does not damage or alter the primary DNA sequence or structure, providing economical access to multi-omic information including epigenetic, mutation, fragmentomic, and chromatin organization signatures. The platform is high-throughput, DNA sequencer-agnostic and seamlessly integrates with standard clinical workflows and sample types (FFPE, tissue, and cfDNA, etc.). These features unlock an array of clinical applications, ranging from drug screening and discovery to disease diagnosis and monitoring.

With a strong team, validated platform and promising results in early cancer diagnosis, the team are gearing up to apply their pioneering platform to deliver superior clinical insights and earlier, less invasive, means of disease diagnosis and monitoring.

**Contact:** www.tagomics.com | info@tagomics.com

## TTP

TTP is a leading product and technology development company based in Cambridge, UK. With over 35 years of experience and a team of more than 300 scientists and engineers, we innovate, implement, and industrialise products that significantly improve the lives of millions. Whether transforming a start-up's blueprint ideas into market-ready products or helping established organisations launch disruptive innovations, we support our clients in driving innovation from first principles, through product design and manufacture to commercialisation.

Our expertise spans a broad spectrum of disciplines in science and engineering. We work on a diverse range of projects in life science and healthcare, encompassing advanced diagnostic systems, cell therapy manufacturing, drug discovery tools, multi-omics, drug delivery systems, biosensing, surgical/imaging technology and digital healthcare solutions. Our comprehensive approach allows us to manage the entire project lifecycle, from opportunity discovery and technology development to product and process development and late-stage troubleshooting, all within our state-of-the-art facilities. Our unique, enabling culture fosters innovation and ingenuity. At TTP, our employees are all deep domain experts who collaborate seamlessly in highly flexible, multi-disciplinary project teams to deliver exceptional results.

**Contact:** www.ttp.com | enquiries@ttp.com

## U-PLOID BIOTECHNOLOGIES***

U-Ploid develops next-generation IVF therapeutics for treating female infertility. More people are planning for children later in life. Egg quality decreases in all women as they enter their mid-30's. U-Ploid's therapeutics improve egg quality within the IVF cycle, generating more eggs capable of supporting a healthy pregnancy.

**Contact:** info@u-ploid.com

## VALIRX

ValiRx accelerates the development of treatments in cancer and women's health to improve patient lives. They provide the scientific, financial and commercial framework to enable the rapid translation of innovative science from early preclinical stages towards clinical development. Inaphaea BioLabs, a subsidiary of ValiRx, is a translational contract research organisation, offering products and services based on its patient-derived cell (PDC) models. These models, across a range of cancer types, are available for use in services, including POC assays, or under license for use in your own laboratory including CROs.

**Contact:** valirx.com | info@valirx.com

****Accelerate@Babraham company*

## VERINNOGEN

verinnogen

Verinnogen's novel technology has been built to act as the interface between the physical and digital worlds, able to do what imaging can't: digitise touch on a large scale. Our contact profiling technology and computational process allows faithful recreation of 3D surfaces without the possibility of optical interference, all contained within a quick and simple process. Our first product, a hand-held pre-clinical tumour measuring device for *in vivo* oncology studies, will reduce the variability associated with subcutaneous tumour volume estimation, improving the quality of pre-clinical data and expediting the translation of novel cancer innovations. With an estimated 60+ million tumour volume measurements being made worldwide, and inter-operator variability of standard methods reported to be over 100%, a quick, easy-to-use but reliable and accurate method is urgently needed. This vital application will form the bedrock of Verinnogen's 3D contact profiling technology, supporting the development of additional features, products, and applications to transform the way we interact with, and measure, 3D surfaces across a multitude of sectors, including human health, agriculture, manufacturing, and security. Working closely with partners and collaborators using a quality-led design approach, Verinnogen looks to enable its customers with a unique set of tools to generate the key data and metrics they need to change the world.

**Contact:** www.verinnogen.com

## VERNALIS RESEARCH

Vernalis RESEARCH a HITGEN Company

Vernalis Research, a HitGen Company, is recognised as a world leader in fragment- and structure-based drug discovery. Based in Cambridge, UK, Vernalis has been developing and applying these methods to challenging projects since 1997. Vernalis has a strong emphasis on combining innovative structural biology, biophysics, and medicinal chemistry to solve problems and tackle targets across therapeutic areas, ranging from oncology to inflammation and CNS disorders. This requires a deep understanding of the techniques involved and a cautious interpretation of the data; an approach grounded on over two decades of developing and applying fragment-based lead discovery to a wide range of therapeutic targets. By combining structural, thermodynamic, and kinetic information from fragment and other hits, we design novel, potent, drug-like molecules. Our successes include generation of lead compounds which inhibit protein-protein interactions and enzymes, leading to pre-clinical candidates for Mcl-1, Bcl-2, Hsp90, FAAH, Chk1 and IRAK4. Vernalis balances an internal portfolio of drug discovery projects with fully integrated research collaborations with academic partners, and biotechnology and pharmaceutical companies.

**Contact:** www.vernalis.com | collaborate@vernalis.com

## FRAME SHIFT BIO-INCUBATOR

The Milner Therapeutics Institute provides space for start-ups and SMEs through the Frame Shift Bio-incubator. Frame Shift provides a unique environment for companies to work side-by-side with start-ups, pharma and academic scientists in an ecosystem physically and culturally designed to spark collaboration and entrepreneurship.

## AVATRIAL


Avatrial: An unparalleled Biomedical Data Universe

Our understanding of health and disease is predicated on disparate snapshots of rudimentary and superficial data from a miniscule, Western-biased, part of the population. Consequently, diseases such as cancer are diagnosed too late and even 'new and advanced' therapies, developed at astonishingly huge cost, typically only offer minor incremental benefit. Avatrial was founded to address this need and aims to assemble the world's most comprehensive and scalable multi-dimensional health and disease dataset and interrogate it to transform our understanding of how cancer begins, to improve diagnosis and to develop transformative therapies.

In disease, Avatrial will routinely collect healthy tissue, cancer tissue and blood samples from patients undergoing surgery around the globe and perform state-of-the-art deep multi-omic characterisation of the samples. The data will be linked with regularly-updated clinical data for all patients. In health, Avatrial will crowdsource longitudinal socio-demographic, environmental, behavioural, physiological and multi-omic data across ages and races.

Avatrial has obtained the expertise, infrastructure, regulatory approvals, contracts and logistic solutions to generate these data as a matter of routine and in a scalable manner. Avatrial is seeking partners to join its mission to deliver a paradigm shift in oncology discovery and therapeutics by leveraging and rapidly expanding unprecedented access to healthy and diseased human tissue and data.

**Contact:** avatrial.life | Professor Kourosh Saeb-Parsy
kourosh.saeb-parsy@avatrial.life

## CLOCK.BIO

clock.bio

Investigating the repair mechanisms of stem cells to better treat age-related diseases. clock.bio is a healthspan/longevity venture that aims to identify novel therapeutic targets for the treatment of age-related disease. Using iPSCs, a proprietary aging-model, and unbiased CRISPR screens, we have validated a way to read genetically encoded rejuvenation programs in human cells.

**Contact:** clock.bio | info@clock.bio

## COSYNE THERAPEUTICS

COSYNE THERAPEUTICS

CoSyne Therapeutics is a computational drug target discovery company based in London and Cambridge, UK. The company's mission is to develop next generation therapeutics to help patients with devastating diseases. Their first goal is to cure brain cancer.

**Contact:** cosyne.com | info@cosyne.com

## EPITOPEA

EPITOPEA

Epitopea is a new transatlantic cancer-immunotherapeutics company with operations in Cambridge and Montreal. Our company builds on the recent discovery of an abundant new class of tumour specific antigen. We will discover additional antigens and prioritise the most promising for exploitation via multiple modalities to achieve our goal: guiding the adaptive immune system to control cancer.

**Contact:** epitopea.com | info@epitopea.com

## HEALTHSPAN BIOTICS

Boosting brain health using nature-inspired methods

Healthspan Biotics use AI and laboratory experiments to identify how certain individuals protect themselves against brain-related diseases such as Alzheimer's disease. They have identified a novel pathway that contributes to the health of neurons and found a beneficial bacteria from our gut that can boost this pathway to promote neuronal health.

**Contact:** www.healthspanbiotics.com | Yizhou Yu – yizhou@healthspanbiotics.com.

## IMMUTRIN

Amyloidosis is a group of rare but very serious, usually fatal diseases caused by the aggregation of the body's own proteins to form amyloid deposits in vital organs. Immutrin Ltd is a Cambridge-based biotech company which is generating transformative antibody treatments for systemic and local amyloidosis.

**Contact:** Mihriban Tuna | info@immutrin.com

## SHIFT BIOSCIENCE

Shift bioscience

We have now directly experienced the devastating collision of the fast pandemic of COVID-19 with the slow pandemics of chronic disease, the latter driving healthcare costs to 1/3 GDP by 2040. Control of biological age with Yamanaka factors promises an effective solution to chronic disease, but risks teratoma formation. Shift Bioscience is focused on rapid discovery of safer biology for age control through an active machine learning approach, promising a new drug class that effectively confronts the increasing challenge of chronic disease.

**Contact:** shiftbioscience.com | hello@shiftbioscience.com

## VIROTHERA


Virothera (formerly Virokine Therapeutics), founded by Dr Ursula Gompels, is engineering novel virus inspired human gene immunotherapy for new cures for infections, autoimmune disease and cancer. Our proprietary technologies can solve the problem of *in vivo* immune cell targeting, utilising gene expression of novel cell membrane antigen complexes and adapted human chemokines, regulators of immune cell delivery. Initially focused on virus infections, we show high protective efficacy for our first products in preclinical *in vivo* models. With rapid genomics discovery, we aim to re-code immunity for new treatments.

**Contact:** virothera.co.uk | info@virothera.co.uk

START CODON

## START CODON COMPANIES

The life science and healthcare venture builder Start Codon (the vision of which was conceived and created together with the Milner Therapeutics Institute) leverages Cambridge's resources to support founders from across the UK.

Start Codon and its dedicated team provide a combination of business support services, facilities, and access to an extensive network of industry leading pharma, biotech and venture capital executives. The newest companies in the Start Codon portfolio are shown here, and others are indicated throughout the Affiliated Company section of the booklet.

## AWEN ONCOLOGY

Awen Oncology

Awen Oncology is developing new therapeutic options for patients suffering from a range of cancerous malignancies. We have identified a breakthrough group of cellular targets for the development of multiple new therapeutic agents in the expanding commercial oncology sector. Our targets have notable cancer-specificity, enabling the development of first in class small molecule inhibitors with excellent therapeutic index potential and clear allied biomarker capacity, both essential to ensure new treatments can be utilised effectively and appropriately in chronic disease management.

Awen Oncology has established and gained traction by identifying small molecules that specifically inhibit an oncogenic transcription factor that was previously deemed to be in an 'undruggable' class of proteins. We will develop clinical candidate inhibitors for this primary target for the treatment of both rare and prevalent cancers. Awen Oncology has high growth potential through further expansion of our unique target class and isolation of new inhibitors of our current target set. Awen Oncology holds a world-leading position in this emerging space, ensuring we can realise our vision of addressing major global unmet clinical needs in oncology.

**Contact:** Ramsay McFarlane – Ramsay@awenoncology.com

## EMM

emm

Emm has developed a biowearable menstrual product to capture baseline data for actionable insights into reproductive health. The product enables an insights platform for co-development of new diagnostics and therapeutics in women's health.

**Contact:** www.emm.co

## INDEGRA THERAPEUTICS

Indegra Therapeutics is an integrin inhibitor drug discovery platform company established in 2022 to unlock new treatments for multiple diseases with significant therapeutic and commercial benefits, including chronic kidney disease (CKD), cancer, NASH, fibrosis, osteoporosis, and eye diseases. With many years of pharma drug discovery experience, and world-class medicinal chemistry know-how, the Indegra team is ideally positioned, in this constantly evolving and hugely underexploited space, to design and exploit new developments with integrin modulatory drugs. Integrins are a druggable target class of 24 extracellular signalling proteins, often upregulated in the disease state, thus offering enhanced tissue targeting opportunities.

With rapid implementation of new advances and knowledge from cutting-edge integrin research, Indegra not only has the ambition to progress small molecule therapeutics, but also to incorporate different and new modalities, such as protein degradation and allosteric targeting. The flagship programme is focused on the design of novel small molecules that target a specific integrin for both CKD and immuno-oncology treatments.

**Contact:** Richard Hatley – rhatley@indegratx.com

## TRIMTECH THERAPEUTICS

As we age, our brains accumulate mis-folded, aggregated proteins that are toxic to neurones. Most age-related brain disorders show characteristic protein deposits that result in neurodegeneration.

Neurodegenerative diseases affect more than 50 million people worldwide and are now the leading cause of death for both men and women in the UK. These diseases, which include Alzheimer's and Huntington's, are caused by protein aggregation inside cells.

TRIMTECH's unique technology targets and degrades aggregated proteins, without affecting non-aggregated forms, offering a solution that is both potent and able to demonstrate outstanding safety.

Their oral therapeutics will provide patient-friendly treatments for a range of neurological, inflammatory and oncological diseases.

TRIMTECH's unique technology was created by the founders in the MRC Laboratory of Molecular Biology and the UK Dementia Research Institute within the University of Cambridge.

**Contact:**
linkedin.com/company/trimtech-therapeutics-limited | Damian Crowther damian@trimtechtherapeutics.com

## AFFILIATED RESEARCH INSTITUTIONS

The Affiliated Research Institutions programme, established in October 2017, now includes ten academic institutions. These partners share our vision of developing new models for research collaboration across industry and academia to transform pioneering science into therapies.

## AFFILIATED VENTURE PARTNERS

The Affiliated Venture Partners programme, operational since October 2017, provides mentoring and potential funding for the start-ups within the Start Codon Venture Builder and the Frame Shift Bio-incubator.


## AFFILIATED SOCIETIES & CHARITIES

We work with and support various societies and charities throughout Cambridge and beyond.

| NO | POSTER TITLE | PRESENTER | INSTITUTION |
|---|---|---|---|
| 1 | Whole genome CRISPR drug sensitivity and resistance screen on squamous cancer cells | Chaozheng Li | *Milner Therapeutics Institute, University of Cambridge* |
| 2 | Drug repurposing approaches in metabolic asssociated steatohepatitis | Fatima Baldo | *Milner Therapeutics Institute, University of Cambridge* |
| 3 | Developing the use of patient-derived intestinal epithelial organoids for arrayed CRISPR screening | Thomas Dennison | *Milner Therapeutics Institute, University of Cambridge* |
| 4 | The MRC-AZ-UoC Functional Genomics Screening Laboratory | Chun Hao Wong | *Milner Therapeutics Institute, University of Cambridge* |
| 5 | Identifying new targets in lung squamous cell carcinoma with single cell transcriptomics of *in vitro* primary patient models | Holly Giles | *Milner Therapeutics Institute, University of Cambridge* |
| 6 | Development of an arrayed CRISPR screen using human airway organoids for target ID and validation | Edvishkha Dias | *Milner Therapeutics Institute, University of Cambridge* |
| 7 | DrugVLAB for exploring chemical, genetic, and disease space with cut edge AI technologies | Sun Kim | *AIGENDRUG* |
| 8 | High efficiency prime-editing approach to install clinically relevant point mutations conferring Cetuximab resistance in colorectal cancer cell lines | Sebastian Lukasiak | *AstraZeneca (Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre)* |
| 9 | Combined gene and drug therapy for chronic myelogenous leukaemia: computational target analyses and therapeutic validation | Cheng Wai Winnie Lei | *Avatrial* |
| 10 | New breakthrough cancer-specific therapeutic targets and small molecule inhibitors | Ramsay McFarlane | *Awen Oncology* |
| 11 | Using cause-and-effect knowledge graphs to find genetic drivers for ALS | Rebecca Morris | *Biorelate* |
| 12 | Harnessing CRISPR-ready ioGlutamatergic neurons and ioMicroglia for drug discovery in neurodegenerative diseases | Roisin Nicoll | *bit.bio* |
| 13 | New modalities for 3D virtual screening of ultra-large chemical spaces | Martin Slater | *Cresset* |
| 14 | Detection of cancer-associated mutations in liquid biopsies for identification of therapeutic targets | Phil Koon | *Cytiva* |
| 15 | Monitoring therapeutic response in NSCLC using liquid biopsy | Phil Koon | *Cytiva* |
| 16 | 3D Genomics illuminates the dark genome | Kishen Chahwala | *Enhanc3D Genomics* |

| NO | POSTER TITLE | PRESENTER | INSTITUTION |
|---|---|---|---|
| 17 | SAFEPATH: Using AI to understand the molecular mechanisms causing safety failures, enabling drug optimisation and turnaround | Jordan Lane | *Ignota Labs* |
| 18 | Using electroporation delivery of Cas9 in challenging cell models – a cross study analysis of performance | Jennifer Hillis | *Joint Astra Zeneca-Cancer Research Horizons Functional Genomics Centre* |
| 19 | High efficiency cell engineering with MaxCyte electroporation: from concept to clinic | Marianna Romito | *MaxCyte* |
| 20 | Multi-omics, cancer biomarker discovery platform for translational researchers | Asta Vasalauskaite | *OmicsChart* |
| 21 | Unbiased selectivity profiling with the Cellular Thermal Shift Assay (CETSA) powered by mass spectrometry detection | Marianne Alksnis | *Pelago Bioscience* |
| 22 | Accessing the inaccessible – reimagining small molecules through AI | Dragana Mitic Potkrajac | *PharmEnable Therapeutics* |
| 23 | SITESEEKER® screening platform to identify novel targets and druggable sites. Case study – Targeted protein degradation of mutant KRAS | Matt Jones and Rebecca Teague | *PhoreMost* |
| 24 | Identifying genetic risk factors for ME/CFS and long COVID: first genetic associations, novel targets, actively protective biology, diagnostics and repurposing opportunities | Steve Gardner | *PrecisionLife* |
| 25 | Who are Selleck Chemicals? | Kristopher Salt | *Selleck Chemicals* |
| 26 | Accelerating data throughput with the Semacyte® Multiplex Platform: unravelling Nutlin-3a cytotoxicity and p53 induction from a cell panel to identify promising biomarkers | Jeroen Verheyen | *Semarion* |
| 27 | Epigenomic profiling of active regulatory elements by enrichment of unmodified CpG dinucleotides | Jack Kennefick | *Tagomics* |

## WITH THANKS TO OUR SPONSORS

Biorelate Selvita

SILVER SPONSORS

bit.bio MaxCyte PELAGO BIOSCIENCE

BRONZE SPONSORS


MILNER
THERAPEUTICS INSTITUTE
Bringing Discoveries to Life


UNIVERSITY OF CAMBRIDGE

contact@milner.cam.ac.uk | www.milner.cam.ac.uk

designed by angie moyes www.fuz.co.uk